Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $310.00 at Mizuho

Key Points

• Mizuho raised its price target on Axsome from $228 to $310 and maintained an "outperform" rating, implying roughly a 38.4% upside from the current share price.
• Axsome reported Q1 revenue of $191.2M, up about 57% year-over-year driven by Auvelity and Sunosi, but missed EPS at a loss of $1.26 versus consensus -$0.85 and remains unprofitable with negative margins.
• The company showed pipeline and regulatory momentum — Auvelity gained approval for agitation in dementia, Axsome submitted an NDA for AXS‑12, and added AXS‑20 to its pipeline — supporting future revenue potential.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) had its price target lifted by equities researchers at Mizuho from $228.00 to $310.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an "outperform" rating on the stock. Mizuho's target price would indicate a potential upside of 38.37% from the stock's current price.

Several other brokerages have also weighed in on AXSM. Guggenheim reissued a "buy" rating and issued a $260.00 price objective on shares of Axsome Therapeutics in a report on Monday. Leerink Partners boosted their price objective on Axsome Therapeutics from $150.00 to $205.00 and gave the company an "outperform" rating in a report on Wednesday, January 28th. Morgan Stanley set a $217.00 price objective on Axsome Therapeutics in a report on Thursday. TD Cowen reissued a "buy" rating on shares of Axsome Therapeutics in a report on Friday. Finally, Wells Fargo & Company boosted their price objective on Axsome Therapeutics from $193.00 to $202.00 and gave the company an "overweight" rating in a report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $243.00.

Axsome Therapeutics Stock Up 8.5%

Shares of NASDAQ AXSM opened at $224.03 on Tuesday. Axsome Therapeutics has a 1 year low of $96.09 and a 1 year high of $234.29. The firm has a market cap of $11.52 billion, a price-to-earnings ratio of -60.71 and a beta of 0.59. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.48 and a current ratio of 1.55. The stock's 50-day simple moving average is $170.95 and its 200-day simple moving average is $162.68.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.41). Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.The business had revenue of $191.20 million for the quarter, compared to analysts' expectations of $191.10 million. The firm's revenue for the quarter was up 57.4% compared to the same quarter last year. As a group, equities analysts anticipate that Axsome Therapeutics will post -1.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, Director Mark Coleman sold 25,000 shares of Axsome Therapeutics stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $161.11, for a total value of $4,027,750.00. Following the completion of the transaction, the director directly owned 47,140 shares in the company, valued at $7,594,725.40. The trade was a 34.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Ari Maizel sold 7,500 shares of Axsome Therapeutics stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $182.42, for a total value of $1,368,150.00. Following the completion of the transaction, the insider owned 7,500 shares of the company's stock, valued at approximately $1,368,150. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 67,878 shares of company stock worth $11,122,891 over the last ninety days. Company insiders own 22.30% of the company's stock.

Hedge Funds Weigh In On Axsome Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of AXSM. Vanguard Group Inc. grew its holdings in Axsome Therapeutics by 6.0% in the 3rd quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company's stock worth $507,739,000 after buying an additional 235,626 shares in the last quarter. Franklin Street Advisors Inc. NC bought a new position in Axsome Therapeutics in the 4th quarter worth approximately $1,826,000. Aberdeen Group plc grew its holdings in Axsome Therapeutics by 15.5% in the 3rd quarter. Aberdeen Group plc now owns 94,648 shares of the company's stock worth $11,495,000 after buying an additional 12,732 shares in the last quarter. TD Asset Management Inc grew its holdings in Axsome Therapeutics by 107.7% in the 3rd quarter. TD Asset Management Inc now owns 44,192 shares of the company's stock worth $5,367,000 after buying an additional 22,914 shares in the last quarter. Finally, Pictet Asset Management Holding SA grew its holdings in Axsome Therapeutics by 20.4% in the 4th quarter. Pictet Asset Management Holding SA now owns 436,063 shares of the company's stock worth $79,643,000 after buying an additional 73,925 shares in the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Q1 revenue beat and strong year-over-year growth: Net product revenue was $191.2M (vs. $191.1M consensus) and up ~57% year-over-year, driven by Auvelity ($153.2M) and Sunosi ($33.9M). This supports continued commercial momentum across core products. Read More.
• Positive Sentiment: Regulatory and pipeline progress: Auvelity received an approval for agitation associated with dementia due to Alzheimer’s disease, and Axsome submitted an NDA for AXS‑12 (cataplexy). The company also added AXS‑20 (PDE10A inhibitor) to the pipeline—these expand addressable markets and future revenue potential. Read More.
• Positive Sentiment: Analyst/broker tone and investor engagement: Broker consensus is a “Moderate Buy,” and management will be participating in multiple investor conferences in May (BofA, fireside chat, etc.), which can boost visibility and help reprice expectations. Read More. Read More.
• Neutral Sentiment: Company events and disclosures: Management hosted a conference call and published a slide deck and transcript; analysts will parse details on unit trends and cost trajectory during conference appearances. Read More.
• Negative Sentiment: EPS miss and continued losses: Reported EPS was a loss of $1.26 vs. consensus -$0.85 (miss), and the company remains unprofitable with negative margins and ROE metrics—this leaves valuation sensitive to execution. Read More.
• Negative Sentiment: Mixed product trends flagged by analysts: Despite strong YoY growth, some analysts note sequential declines in Auvelity and Sunosi sales and call management’s peak revenue targets ambitious, which could limit upside if sustained. Read More.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome's pipeline includes several late-stage and approved product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.